Addex Therapeutics Ltd (SW:ADXN) — Market Cap & Net Worth
Market Cap & Net Worth: Addex Therapeutics Ltd (ADXN)
Addex Therapeutics Ltd (SW:ADXN) has a market capitalization of $6.98 Million (CHF5.52 Million) as of June 19, 2026. Listed on the SW stock exchange, this Switzerland-based company holds position #27865 globally and #211 in its home market, demonstrating a -3.06% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Addex Therapeutics Ltd's stock price CHF0.04 by its total outstanding shares 147839777 (147.84 Million). Review Addex Therapeutics Ltd balance sheet liabilities to assess the company's total debt and financial obligations.
Addex Therapeutics Ltd Market Cap History: 2015 to 2026
Addex Therapeutics Ltd's market capitalization history from 2015 to 2026. Data shows change from $532.69 Million to $8.30 Million (-32.91% CAGR).
Addex Therapeutics Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Addex Therapeutics Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
59.85x
Addex Therapeutics Ltd's market cap is 59.85 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $343.91 Million | $17.33K | -$3.15 Million | 19846.12x | N/A |
| 2017 | $428.02 Million | $499.89K | -$3.28 Million | 856.23x | N/A |
| 2018 | $420.55 Million | $6.04 Million | -$1.64 Million | 69.58x | N/A |
| 2019 | $306.53 Million | $2.76 Million | -$14.78 Million | 110.95x | N/A |
| 2020 | $371.95 Million | $3.61 Million | -$12.86 Million | 102.95x | N/A |
| 2021 | $194.39 Million | $2.92 Million | -$15.41 Million | 66.65x | N/A |
| 2022 | $18.80 Million | $1.42 Million | -$20.80 Million | 13.22x | N/A |
| 2023 | $8.60 Million | $1.61 Million | -$10.56 Million | 5.33x | N/A |
| 2024 | $10.69 Million | $410.04K | $7.06 Million | 26.07x | 1.52x |
| 2025 | $10.35 Million | $173.00K | -$6.73 Million | 59.85x | N/A |
Competitor Companies of ADXN by Market Capitalization
Companies near Addex Therapeutics Ltd in the global market cap rankings as of June 19, 2026.
Key companies related to Addex Therapeutics Ltd by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #221 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #445 globally with a market cap of $62.84 Billion USD.
- UCB SA (BR:UCB): Ranked #547 globally with a market cap of $49.68 Billion USD ( €42.50 Billion EUR).
- Argen-X (BR:ARGX): Ranked #573 globally with a market cap of $47.14 Billion USD ( €40.32 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #221 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $451.63 |
| #445 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $62.84 Billion | $609.94 |
| #547 | UCB SA | BR:UCB | $49.68 Billion | €249.20 |
| #573 | Argen-X | BR:ARGX | $47.14 Billion | €762.80 |
Addex Therapeutics Ltd Historical Marketcap From 2015 to 2026
Between 2015 and today, Addex Therapeutics Ltd's market cap moved from $532.69 Million to $ 8.30 Million, with a yearly change of -32.91%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CHF8.30 Million | -19.86% |
| 2025 | CHF10.35 Million | -3.15% |
| 2024 | CHF10.69 Million | +24.35% |
| 2023 | CHF8.60 Million | -54.27% |
| 2022 | CHF18.80 Million | -90.33% |
| 2021 | CHF194.39 Million | -47.74% |
| 2020 | CHF371.95 Million | +21.34% |
| 2019 | CHF306.53 Million | -27.11% |
| 2018 | CHF420.55 Million | -1.75% |
| 2017 | CHF428.02 Million | +24.46% |
| 2016 | CHF343.91 Million | -35.44% |
| 2015 | CHF532.69 Million | -- |
End of Day Market Cap According to Different Sources
On Jun 19th, 2026 the market cap of Addex Therapeutics Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $6.98 Million USD |
| MoneyControl | $6.98 Million USD |
| MarketWatch | $6.98 Million USD |
| marketcap.company | $6.98 Million USD |
| Reuters | $6.98 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Addex Therapeutics Ltd
Addex Therapeutics Ltd discovers, develops, and commercializes small-molecule pharmaceutical products for neurological disorders in Switzerland. The company focuses on the discovery of G-protein coupled receptors and enzymes. Its lead programs include Dipraglurant, which is in phase 1 clinical trial for the treatment of post-stroke/TBI recovery, as well as to treat Parkinson's disease levodopa-in… Read more